RxDoctor Payments Data

Nancy Sondgeroth

Family · Aurora, ILNPI 1770950842

Payments from drug & device makers

$9,956in general payments, 2019–2025

Across 572 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Novo Nordisk$710
  • Nestle Healthcare Nutrition Inc.$598
  • Bayer$395
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$9,956100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,956 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$99,753
Medicare patients
145
Services billed
1,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate14$35,143
OzempicSemaglutide16$20,264
JanuviaSitagliptin Phosphate21$14,865
JardianceEmpagliflozin16$14,481
UbrelvyUbrogepant13$13,083
FarxigaDapagliflozin Propanediol12$12,761
Breo ElliptaFluticasone/Vilanterol16$7,707
XareltoRivaroxaban11$5,964
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$5,010
Albuterol Sulfate HfaAlbuterol Sulfate95$3,244
PremproEstrogen,con/M-Progest Acet11$2,769
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,465
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc23$2,259
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$1,968
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$1,890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto$94$41,10725 claims
Novo NordiskOzempic$710$20,26416 claims
MerckJanuvia$127$14,86521 claims
Boehringer IngelheimJardiance$66$14,48116 claims
AbbVieUbrelvy$2,627$13,08313 claims
AstraZenecaFarxiga$1,058$12,76112 claims
GSKBreo Ellipta$180$7,70716 claims
PfizerPrempro$234$2,76911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Aurora

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →